Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Carboplatin with or without Trastuzumab in Metastatic Breast Cancer
NCT00191451Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2004
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine in breast cancer (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Tumor Response up to 3.5 years. Started Apr 2004; status: completed.
02
Drugs
gemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00191451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191451.